Walvax BioTech receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Walvax BioTech (300142)
Walvax BioTech stock price live, this page displays SZ 300142 stock exchange data. View the 300142 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Walvax BioTech real time stock price chart below.
What Is the Walvax BioTech Stock Price Today?
The Walvax BioTech stock price today is 12.27.
What Is the Stock Symbol for Walvax BioTech?
The stock symbol for Walvax BioTech is "300142."
What Stock Exchange Does Walvax BioTech Trade On?
Walvax BioTech is listed and trades on the Shenzhen stock exchange.
Is Walvax BioTech a Good Stock to Buy?
Determining whether Walvax BioTech—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 300142 quote. (ISIN: CNE100000WN2)
What Is the Walvax BioTech Stock Price Today?
The Walvax BioTech stock price today is 12.27.
What Is the Stock Symbol for Walvax BioTech?
The stock symbol for Walvax BioTech is "300142."
What Stock Exchange Does Walvax BioTech Trade On?
Walvax BioTech is listed and trades on the Shenzhen stock exchange.
Is Walvax BioTech a Good Stock to Buy?
Determining whether Walvax BioTech—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 300142 quote. (ISIN: CNE100000WN2)
Shenzhen
Currency in CNY
12.27
+0.27(+2.25%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.82
12.29
52 wk Range
10.88
16.23
300142 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.8212.29
52 wk Range
10.8816.23
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.25%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.25%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
300142 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Sell
Price Target
8.00
Downside
-34.80%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
Walvax BioTech receives Investment Bank Analyst Rating Update- Investing.com
Pro
Walvax BioTech receives Investment Bank Analyst Rating Update- Investing.com
Pro
Walvax BioTech receives Investment Bank Analyst Rating Update- Investing.com
Pro- Walvax BioTech receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Walvax BioTech receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Walvax BioTech receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Walvax BioTech receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Walvax BioTech receives Investment Bank Analyst Rating Update- Investing.com
Pro- Walvax BioTech receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell
Analyst Ratings
0 Buy
0 Hold
1 Sell
Ratings:
1 analysts
Overall Consensus
Strong Sell
Analysts 12-Month Price Target:
Average 8.00
(-34.80% Downside)
Earnings
Latest Release
Apr 28, 2026
EPS / Forecast
0.07 / 0.04
Revenue / Forecast
443.85M / 731.34M
Compare 300142 to Peers and Sector
Metrics to compare | 300142 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300142PeersSector | |
|---|---|---|---|---|
P/E Ratio | 67.2x | 36.3x | −0.3x | |
PEG Ratio | 0.58 | −0.38 | 0.00 | |
Price/Book | 2.6x | 1.8x | 2.6x | |
Price / LTM Sales | 8.0x | 5.8x | 3.0x | |
Upside (Analyst Target) | −33.7% | 58.5% | 56.3% | |
Fair Value Upside | Unlock | 12.1% | 9.8% | Unlock |
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Walvax BioTech (300142) Stock Price Today?
The Walvax BioTech stock price today is 12.27 CNY.
What Stock Exchange Does Walvax BioTech Trade On?
Walvax BioTech is listed and trades on the Shenzhen Stock Exchange.
What Is the Stock Symbol for Walvax BioTech?
The stock symbol for Walvax BioTech is "300142."
Does Walvax BioTech Pay Dividends? What’s The Current Dividend Yield?
The Walvax BioTech dividend yield is 1.25%.
What Is the Walvax BioTech Market Cap?
As of today, Walvax BioTech market cap is 19.62B CNY.
What Is Walvax BioTech's Earnings Per Share (TTM)?
The Walvax BioTech EPS (TTM) is 0.18.
When Is the Next Walvax BioTech Earnings Date?
Walvax BioTech will release its next earnings report on Aug 29, 2026.
From a Technical Analysis Perspective, Is 300142 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Walvax BioTech Stock Split?
Walvax BioTech has split 5 times.
How Many Employees Does Walvax BioTech Have?
Walvax BioTech has 1981 employees.
What is the current trading status of Walvax BioTech (300142)?
As of Jul 29, 2026, Walvax BioTech (300142) is trading at a price of 12.27 CNY, with a previous close of 12.00 CNY. The stock has fluctuated within a day range of 11.82 CNY to 12.29 CNY, while its 52-week range spans from 10.88 CNY to 16.23 CNY.
What Is Walvax BioTech (300142) Price Target According to Analysts?
The average 12-month price target for Walvax BioTech is 8.00 CNY, with a high estimate of 8 CNY and a low estimate of 8 CNY. 0 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Sell. The stock has an -34.80% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.